Wednesday, February 6, 2019 Daily Archives

Regeneron plans to expand Irish biomanufacturing site again

by

Regeneron has applied to build a three-storey facility as part of a reported €200 million ($228 million) expansion at its Limerick site. Biopharma firm Regeneron has applied for a 10 year permission to add a three-storey 10,200 m2 administration and laboratory building with associated plant and equipment to its manufacturing site in Ballycummin, Limerick, Ireland. The firm is also hoping to convert a temporary induction/training center and facility workshop to permanent use, as well as build a carpark, Limerick City…

February 6, 2019

Madison expansion will add commercial capacity, says Catalent

by

Plans to invest $200 million laid down last year will put Catalent in a position to offer commercial manufacturing from its Madison, Wisconsin facility, the CDMO says. In November 2018, contract development and manufacturing organization (CDMO) Catalent announced its intentions to invest across its two biomanufacturing sites. The board laid down plans to plough $100 million (€88 million) into its Madison, Wisconsin plant to add a fourth and fifth biomanufacturing train. During Catalent’s second quarter FY2019 financial call this week,…

February 6, 2019

Beyond approvals: Top 10 cell and gene therapy milestones

by

M&A, global partnerships and product approvals have all propelled regenerative medicines into the public discourse. We present the breakthroughs of 2018 and look at where the sector will head in 2019. The “new frontier of medicine†arrived in the US in 2017 through the approval of chimeric antigen receptor (CAR) T-Cell therapies Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), and gene therapy Luxturna (voretigene neparvovec). But it was last year, 2018, which delivered the true potential of this burgeoning sector into…

February 6, 2019

Thermo Fisher to make T cells for Torque at new NJ plant

by

Thermo Fisher will staff and operate a modular and fully-closed cell therapy facility in New Jersey on behalf of Torque. The 10,000 square-foot facility in Princeton, New Jersey is set to come online in 2019 and will support Torque’s immuno-oncology ‘Deep-Primed T Cell’ candidates. The products use the firm’s cell process engineering technologies, which do not require genetic engineering of the T cells, and lead candidate TRQ1501 (Deep IL-15 primed T cells) is set to begin Phase I/II clinical trials…

February 6, 2019